Lyell Immunopharma Inc (LYEL) Stock Price, Quote & News

Company Profile

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 695 0677

Website: www.lyell.com

Address:

201 Haskins Way, South San Francisco, United States

Doozio Dec. 5 at 2:42 AM

$LYEL 👀 MAMA another biotech STOK going from MLYS’s TTWO BILI’s during 🐒🍌🧠⏰♾️

0 · Reply

dbr_island Dec. 3 at 3:20 PM

$LYEL watching….. 🚨EPOW🚨 just received a $30M contract AH That is HUGE for a tiny company This should be at least $2 🎯✅ I’m even willing to put some of my TSLA COIN profits into EPOW👇💰💰💰

0 · Reply

fantastex Nov. 28 at 6:04 PM

$LYEL waiting for this to hit 20.50 again for loading again. But I May wait 18.90

0 · Reply

Hopipaytrader Nov. 26 at 10:07 PM

$LYEL nice charts in bio

1 · Reply

Mdugs Nov. 24 at 4:07 PM

$LYEL 52 week high…

0 · Reply

JarvisFlow Nov. 24 at 2:56 PM

HC Wainwright & Co. has updated their rating for Lyell Immunopharma ( $LYEL ) to Neutral with a price target of 20.

0 · Reply

fantastex Nov. 22 at 5:38 PM

$LYEL many sleepers on this. Aquisition play from either $BMY or other big players next year , quite likely imho.

0 · Reply

terra987 Nov. 17 at 3:40 PM

$LYEL Since the data will be announced during an oral presentation at the ASH, it should at least be as expected. I hope data will be even better ...

0 · Reply

Mdugs Nov. 14 at 7:50 PM

$LYEL interesting to see them acquire something. While cash is tight I think they either have bad trial results coming… or very good so they can raise more cash. Anyone still here?

1 · Reply

d_risk Nov. 12 at 10:26 PM

$LYEL - Lyell Immunopharma Inc. Common Stock - 10Q - Updated Risk Factors LYEL’s latest 10-Q details heightened risks in manufacturing, clinical trials, supply chain, IP rights, Nasdaq compliance, capital needs, and commercialization, with new focus on acquisitions, workforce reductions, regulatory scrutiny, and expanded legal and tax exposures. #ManufacturingRisks #ClinicalTrials #Biotechnology #TaxExposure #LegalRisks #WorkforceReduction #Acquisitions #CapitalNeeds #RegulatoryCompliance #IntellectualProperty #SupplyChain 🟢 Added 🟠 Removed https://d-risk.ai/LYEL/10-Q/2025-11-12

0 · Reply

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025

Nov 10, 2025, 7:30 AM EST - 25 days ago

Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer

Nov 3, 2025, 9:00 AM EST - 4 weeks ago

Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Sep 3, 2025, 8:00 AM EDT - 3 months ago

Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee

Sep 2, 2025, 4:05 PM EDT - 3 months ago

Lyell Immunopharma Announces Participation in September Investor Conferences

Aug 12, 2025, 4:05 PM EDT - 4 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025

Jul 25, 2025, 8:00 AM EDT - 4 months ago

Lyell Immunopharma Announces up to $100 Million Equity Private Placement

Jul 22, 2025, 9:02 AM EDT - 4 months ago

Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement

Jun 23, 2025, 5:00 PM EDT - 5 months ago

Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series

Jun 17, 2025, 6:30 AM EDT - 6 months ago

Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma

Jun 9, 2025, 4:05 PM EDT - 6 months ago

Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments

Jun 4, 2025, 4:05 PM EDT - 6 months ago

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

May 13, 2025, 4:05 PM EDT - 7 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025

May 1, 2025, 9:00 AM EDT - 7 months ago

Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025

$Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma$

Apr 15, 2025, 9:00 AM EDT - 8 months ago

Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell Lymphoma

Mar 11, 2025, 4:05 PM EDT - 9 months ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024

Feb 18, 2025, 4:05 PM EST - 10 months ago

Lyell Immunopharma Announces Participation in Upcoming Investor Conferences

Jan 9, 2025, 9:00 AM EST - 11 months ago

Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference

Dec 9, 2024, 9:00 PM EST - 1 year ago

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

Nov 5, 2024, 9:30 AM EST - 1 year ago

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

Oct 31, 2024, 4:00 PM EDT - 1 year ago

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

Oct 25, 2024, 9:24 AM EDT - 1 year ago

Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth

Oct 24, 2024, 4:00 PM EDT - 1 year ago

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 24, 2024, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

Jun 26, 2024, 7:00 AM EDT - 1 year ago

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

May 7, 2024, 4:05 PM EDT - 1 year ago

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

May 6, 2024, 8:00 AM EDT - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

Apr 16, 2024, 6:25 PM EDT - 1 year ago

Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts

Mar 5, 2024, 4:30 PM EST - 1 year ago

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

Feb 28, 2024, 4:05 PM EST - 1 year ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

Feb 26, 2024, 4:05 PM EST - 1 year ago

Lyell Immunopharma Announces Participation in March Investor Conferences

Jan 3, 2024, 4:05 PM EST - 2 years ago

Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference

Nov 10, 2023, 2:23 PM EST - 2 years ago

Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL

Nov 9, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

Nov 7, 2023, 4:05 PM EST - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Sep 27, 2023, 9:00 AM EDT - 2 years ago

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Sep 11, 2023, 8:00 AM EDT - 2 years ago

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell's CAR T-Cell Therapy on Cellares' Cell Shuttle Platform

Aug 31, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma to Participate in Upcoming Investor Conferences

Aug 26, 2023, 9:29 AM EDT - 2 years ago

Lyell Immunopharma: Once Huge IPO Now Waiting For Clinical Data

Aug 8, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

Jul 5, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Appoints Matthew Lang as Chief Business Officer

Jun 16, 2023, 10:47 AM EDT - 2 years ago

Why Shares of Lyell Immunopharma Jumped This Week

May 4, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023

May 2, 2023, 4:05 PM EDT - 2 years ago

Lyell Immunopharma to Participate in BofA Securities Healthcare Conference

Feb 28, 2023, 4:05 PM EST - 3 years ago

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

Jan 3, 2023, 4:05 PM EST - 3 years ago

Lyell Immunopharma to Participate in 41st Annual J.P. Morgan Healthcare Conference

Dec 15, 2022, 7:00 AM EST - 3 years ago

Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer

Dec 1, 2022, 4:05 PM EST - 3 years ago

Lyell Immunopharma to Participate in BofA Securities Biotech Conference

Doozio Dec. 5 at 2:42 AM

$LYEL 👀 MAMA another biotech STOK going from MLYS’s TTWO BILI’s during 🐒🍌🧠⏰♾️

0 · Reply

dbr_island Dec. 3 at 3:20 PM

0 · Reply

fantastex Nov. 28 at 6:04 PM

$LYEL waiting for this to hit 20.50 again for loading again. But I May wait 18.90

0 · Reply

Hopipaytrader Nov. 26 at 10:07 PM

$LYEL nice charts in bio

1 · Reply

Mdugs Nov. 24 at 4:07 PM

$LYEL 52 week high…

0 · Reply

JarvisFlow Nov. 24 at 2:56 PM

HC Wainwright & Co. has updated their rating for Lyell Immunopharma ( $LYEL ) to Neutral with a price target of 20.

0 · Reply

fantastex Nov. 22 at 5:38 PM

$LYEL many sleepers on this. Aquisition play from either $BMY or other big players next year , quite likely imho.

0 · Reply

terra987 Nov. 17 at 3:40 PM

$LYEL Since the data will be announced during an oral presentation at the ASH, it should at least be as expected. I hope data will be even better ...

0 · Reply

Mdugs Nov. 14 at 7:50 PM

$LYEL interesting to see them acquire something. While cash is tight I think they either have bad trial results coming… or very good so they can raise more cash. Anyone still here?

1 · Reply

d_risk Nov. 12 at 10:26 PM

0 · Reply

None_ Nov. 12 at 3:11 AM

$LYEL https://www.fiercebiotech.com/biotech/lyell-signs-185m-deal-impressive-phase-1-stage-colorectal-cancer-car-t

0 · Reply

fantastex Nov. 3 at 2:26 PM

$LYEL 7/12....

0 · Reply

fantastex Oct. 31 at 12:41 PM

$LYEL so nervous, but I feel inside myself that this will skyrocket sooner or later

1 · Reply

Hopipaytrader Oct. 22 at 5:07 PM

$LYEL anyone see the overnight -25%

0 · Reply

Hopipaytrader Oct. 22 at 3:25 AM

$LYEL ok deep handle time?

0 · Reply

Hopipaytrader Oct. 17 at 12:28 PM

$LYEL good morning

0 · Reply

fantastex Oct. 17 at 11:20 AM

$LYEL the big pump is yet to come.

0 · Reply

Hopipaytrader Oct. 16 at 12:54 AM

$LYEL beauty

2 · Reply

fantastex Oct. 6 at 8:03 PM

$LYEL if $SPRB went up 1600% this Company with breakthrough ph2/ph3 phase should go at 200$ overnight! Lol Such

0 · Reply

ObscureCandle Oct. 5 at 11:00 AM

$LYEL Biotech speculation. Pre-revenue stage. Chart shows high risk/reward. No pattern recognition.

1 · Reply

Market Cap	473.37M
Revenue (ttm)	60,000.00
Net Income (ttm)	-342.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-571,650.00%
Debt to Equity Ratio	0.00

Volume	93,500
Avg Vol	36,798
Day's Range	N/A - N/A
Shares Out	21.22M
Stochastic %K	64%
Beta	-0.11
Analysts	Hold
Price Target	$16.00